Ascentage Pharma announced that China’s National Medical Products Administration granted a Breakthrough Therapy Designation for its Bcl-2 inhibitor, lisaftoclax, in combination with acalabrutinib. The designation applies to the first-line treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not previously received systemic therapy. This regulatory milestone accelerates development and review pathways for the drug candidate in China. Ascentage Pharma is a global, commercial-stage integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel therapies to address unmet medical needs in cancer.
